Nanobiotix (NASDAQ:NBTX) Hits New 52-Week High – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $30.35 and last traded at $30.31, with a volume of 175540 shares trading hands. The stock had previously closed at $23.60.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NBTX. Leerink Partners set a $14.00 target price on Nanobiotix in a research note on Thursday, September 18th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Friday, September 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Nanobiotix Stock Performance

The business has a 50 day simple moving average of $13.41 and a 200-day simple moving average of $7.50.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.